Role of Epidermal Growth Factor-Triggered PI3K/Akt Signaling in the Migration of Medulloblastoma-Derived Cells
- 166 Downloads
Medulloblastoma (MB) is the most common brain cancer diagnosed among children. The cellular pathways that regulate MB invasion in response to environmental cues remain incompletely understood. Herein, we examine the migratory response of human MB-derived Daoy cells to different concentration profiles of Epidermal Growth Factor (EGF) using a microfluidic system. Our findings provide the first quantitative evidence that EGF concentration gradients modulate the chemotaxis of MB-derived cells in a dose-dependent manner via the EGF receptor (EGF-R). Data illustrates that higher concentration gradients caused increased number of cells to migrate. In addition, our results show that EGF-induced receptor phosphorylation triggered the downstream activation of phosphoinositide-3 kinase (PI3K)/Akt pathway, while its downstream activation was inhibited by Tarceva (an EGF-R inhibitor), and Wortmannin (a PI3K inhibitor). The treatment with inhibitors also severely reduced the number of MB-derived cells that migrated towards increasing EGF concentration gradients. Our results provide evidence to bolster the development of anti-migratory therapies as viable strategies to impede EGF-stimulated MB dispersal.
KeywordsChemotaxis EGF microfluidics Daoy PI3K/Akt
This work has been supported by The National Institutes of Health (R21 CA 118255 and U54 MICHOR), The Pediatric Brain Tumor Foundation, and PSC-CUNY (No. 69424). The authors wish to thank Ms. Jennifer Rico for her technical assistance in this work.
- 2.Abouantoun, T. J., and T. J. Macdonald. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol. Cancer Ther. 8(5):1137–1147, 2009.CrossRefGoogle Scholar
- 4.Cadena, D. L., C. L. Chan, and G. N. Gill. The intracellular tyrosine kinase domain of the epidermal growth factor receptor undergoes a conformational change upon autophosphorylation. J. Biol. Chem. 269(1):260–265, 1994.Google Scholar
- 9.Duffner, P. K., M. E. Horowitz, J. P. Krischer, P. C. Burger, M. E. Cohen, R. A. Sanford, H. S. Friedman, and L. E. Kun. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro. Oncol. 1(2):152–161, 1999.Google Scholar
- 14.Herbst, R. S. Erlotinib. Clin. Adv. Hematol. Oncol. 3(2):124–141, 2005.Google Scholar
- 15.Hernan, R., R. Fasheh, C. Calabrese, A. J. Frank, K. H. Maclean, D. Allard, R. Barraclough, and R. J. Gilbertson. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 63(1):140–148, 2003.Google Scholar
- 16.Hirata, A., S. Ogawa, T. Kometani, T. Kuwano, S. Naito, M. Kuwano, and M. Ono. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62(9):2554–2560, 2002.Google Scholar
- 22.Kruger, J. S., and K. B. Reddy. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol. Cancer Res. 1(11):801–809, 2003.Google Scholar
- 43.Zohrabian, V. M., B. Forzani, Z. Chau, R. Murali, and M. Jhanwar-Uniyal. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 29(1):119–123, 2009.Google Scholar